期刊文献+

托伐普坦致癫痫发作1例 被引量:2

One case of epileptic seizures induced by tolvaptan
原文传递
导出
摘要 托伐普坦(tolvaptan)是新型口服利尿药,2009年在美国和英国上市。2011年9月在我国上市,由日本大冢制药株式会社开发,是选择性非肽类血管加压素V2受体拮抗剂,通过拮抗血管加压素的作用使尿液中水排泄量增加,提高游离水的清除率,降低尿液渗透压,增加血钠水平,但同时又不改变尿液钠钾分泌及影响血钾水平:适用于超容性和等容性低钠血症伴心力衰竭、肝硬化和抗利尿激素分泌异常综合征的治疗。
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2015年第9期687-688,共2页 Chinese Journal of New Drugs and Clinical Remedies
关键词 托伐普坦 利尿药 癫痫 药物不良反应 tolvaptan diuretics epilepsy adverse drug reactions
  • 相关文献

参考文献4

  • 1WANG X, GATFONE V 2nd, HARRIS PC, et al. Effectiveness of vasopressin V2 receptor antagonists 0PC- 31260 and 0PC- 41061 on polycystic kidney disease development in the PCK rat [J]. J Am Sac Nephrol, 2005, 16(4): 846-851.
  • 2黄震华.伴有低钠血症的心力衰竭治疗新药——托伐普坦[J].中国新药与临床杂志,2011,30(5):321-324. 被引量:5
  • 3GHEORGHIADE M, GATYIS WA, O'CONNOR CM, et ol. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial[J]. JAMA, 2004, 291(16) : 1963-1971.
  • 4Medicines and Healthcare Products Regulatory Agency. Tolvaptan: over- rapid increase in serum sodium and risk of serious neurological events[EB/OL]. (2012-04-20)[2015-05- 02]. https://www.gov.uk/drug-safety-update.

二级参考文献19

  • 1OREN RM. Hyponatremia in congestive heart failure[J]. Am J Cardiol, 2005, 95(9A): 2B-7B.
  • 2SIRAGY HM. Hyponatremia, fluid-electrolyte disorders, and the syndrome of inappropriate antidiuretic hormone secretion: diagnosis and treatment options[J]. Endocr Pract, 2006, 12(4): 446-457.
  • 3CAWLEY MJ. Hyponatremia: current treatment strategies and the role of vasopressin antagonists[J]. Ann Pharmacother, 2007, 41(5): 840-850.
  • 4UPADHYAY A, JABER BL, MADIAS NE. Epidemiology of hyponatremia [J]. Semin Nephrol, 2009, 29(3): 227-238.
  • 5PLOSKER GL. Tolvaptan[J]. Drugs, 2010, 70(4) : 443-454.
  • 6CHEN MC, CHANG HW, CHENG CI, et al. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy [J]. Cardiology, 2003, 100(3): 136-142.
  • 7DECAUX G, SOUPART A, VASSART G. Non-peptide arginine- vasopressin antagonists : the vaptans [J]. Lancet, 2008, 371 (9624) : 1624-1632.
  • 8ALI F, GUGLIN M, VAITKEVICIUS P, et al. Therapeutic potential of vasopressin receptor antagonists[J]. Drugs, 2007, 67 (6) : 847-858.
  • 9COSTELLO-BOERRIGTER LC, BOERRIGTER G, BURNETT JC Jr. Pharmacology of vasopressin antagonists[J]. Heart Fail Rev, 2009, 14(2): 75-82.
  • 10CHATTERJEE K. Neurohormonal activation in congestive heart failure and the role of vasopressin[J]. Am J Cardiol, 2005, 95 (9A) : 8B-13B.

共引文献4

同被引文献8

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部